{
}
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
In September, multiple biotech companies announced significant layoffs, with Inventprise cutting 7% of its workforce, bluebird bio reducing 25%, and Athira Pharma laying off 70% after a failed trial. Other notable reductions included Charles River Laboratories (3%), Cidara Therapeutics (30%), and Astellas Gene Therapies impacting around 100 employees. The trend reflects ongoing challenges in the biotech sector, with companies restructuring to focus on core projects and manage costs.
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
The DAX index ended its seven-session winning streak, closing at 20,346 after reaching a record high of 20,462. The market may face profit-taking or setbacks, with key support levels at 20,017 and 20,000, while resistance is noted at 20,400 and the record high.
UBS AG maintains a "Neutral" rating on Bayer shares with a target price of 22 euros, as the company faces a 40.1% decline since early 2024. Analyst Geoff Haire notes that a potential ceasefire in Ukraine could lower gas prices, benefiting the chemical sector. Bayer's shares rose 0.3% to EUR 20.08, indicating a 9.59% upside potential ahead of its Q4 2024 earnings report on March 5, 2025.
UBS has maintained a "Neutral" rating for Bayer, setting a target price of 22 euros. Analyst Geoff Haire highlighted that a potential ceasefire between Russia and Ukraine could lower gas prices, benefiting companies like BASF, Covestro, Lanxess, and Yara in the European chemical sector.
UBS has maintained a "Neutral" rating for Bayer with a target price of 22 euros. Analyst Geoff Haire highlighted that a potential ceasefire between Russia and Ukraine could lower gas prices significantly, benefiting companies like BASF, Covestro, Lanxess, and Yara in the European chemicals sector.
UBS has maintained a "Neutral" rating for Bayer shares with a target price of €22, as discussions around the impact of Russian gas returning to Europe continue. Bayer's stock rose 0.3% to €20.08, showing a potential upside of 9.59% from the target, despite a 40.1% decline since the start of 2024. The company is set to release its Q4 2024 results on March 5, 2025.
Bayer AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
United States Dollar
Bayer AG
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
Amgen Inc.
USA
George Yancopoulos
Show more
14:20 18.12.2024
biotech sector faces significant layoffs amid strategic shifts and acquisitions
18:24 16.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
United States Dollar
Merck & Co., Inc.
Amgen Inc.
Alkem Laboratories Limited
Mylan Pharmaceuticals Inc.
Aurobindo Pharma Limited
Teva Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Limited
Glenmark Pharmaceuticals Limited
CIPLA LTD
Sandoz Group AG
Pfizer Inc.
Bayer AG
Hikma Pharmaceuticals PLC
AstraZeneca PLC
Novartis AG
Torrent Pharmaceuticals Limited
Sanofi
IND
ROU
BEL
HUN
DNK
POL
IDN
SGP
ARE
BRA
ZAF
FRA
THA
MEX
CZE
GBR
CHL
AUT
SAU
SWE
NOR
NLD
USA
ARG
MYS
SVK
CAN
NZL
LKA
JPN
DEU
RUS
KOR
CHN
VNM
Nidhi Bhavsar
Show more
13:09 16.12.2024
global growth trends in the crispr and cas gene market to 2033
United States Dollar
Bayer AG
Bio-Rad Laboratories, Inc.
Pluristem Therapeutics Inc.
Genscript Biotech Corporation
AstraZeneca PLC
Qiagen N.V.
Hologic, Inc.
Cellectis S.A.
Takara Bio Inc.
Vertex Pharmaceuticals Inc
Thermo Fisher Scientific Inc.
Sigma-Aldrich Co. LLC
Regeneron Pharmaceuticals Inc
Editas Medicine Inc
IND
GBR
ESP
CAN
AUS
ITA
IDN
JPN
BRA
DEU
FRA
RUS
KOR
CHN
USA
Show more
15:27 13.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
United States Dollar
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Bayer AG
Immunomedics Inc.
Genentech
Amgen Inc.
Sanofi
USA
FRA
John S. Reed
Houman Ashrafian
Daniel O'Day
Merdad Parsey
Dietmar Berger
Show more
11:20 13.12.2024
DAX Breaks Winning Streak After Reaching New Record High
09:00 10.12.2024
UBS Maintains Neutral Rating on Bayer with Target Price of 22 Euros
14:38 09.12.2024
UBS Maintains Neutral Rating on Bayer with Target Price of 22 Euros
United States Dollar
Euro
Covestro AG
BASF
LANXESS
Bayer AG
UBS AG
RUS
DEU
UKR
Geoff Haire
Show more
14:28 09.12.2024
UBS Maintains Neutral Rating for Bayer Amid European Gas Market Concerns
13:36 09.12.2024
UBS Maintains Neutral Rating on Bayer Shares with Target Price of 22 Euros
13:29 09.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Startups & Entrepreneurship
Cryptocurrency Trends
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Government Economic Policies
Central Bank Actions
Central Banks and Digital Currencies
Fintech Startups
Private Equity Deals
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Crypto Policies and Governance
Banking Regulations
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
United States Dollar
Euro
Chinese Yuan
Egyptian Pound
Hong Kong Dollar
Indian Rupee
New Taiwan Dollar
People: